TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice.
Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, and Amy Rosenfeld
Click arrow to play
Download TWiV 881 (67 MB .mp3, 112 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Monoclonal antibody provides broad hantavirus protection (Sci Transl Med) 9:47
- Prometheus Project (TWiV 578) 10:28
- Oral antiviral related to Remdesivir (Sci Transl Med) 48:42
- Letters read on TWiV 881 1:13:46
- Timestamps by Jolene. Thanks!
Weekly Picks 1:35:55
Dickson – World’s tallest wooden building
Amy – Virus hunter in the Wuhan market
Rich – WorldPop (example)
Vincent – Karst Stone Paper
Neva – Can we vaccinate against EBV? and Paul Sutter reading a science paper
Intro music is by Ronald Jenkees
Send your virology questions and comments to firstname.lastname@example.org
This episode was very interesting to me personally. In 2012, my best friend from high school died in Reno at age 64 from Hantavirus. He contracted it after cleaning out an old mouse-infested shed. His clinical course was remarkably similar to that of severe Covid-19. He appeared to improve after being in the ICU on a ventilator for a couple of weeks, then worsened again and died during a second ICU admission. They threw the whole kitchen sink of therapeutics at him, but it was clear they had no idea how to treat him. It doesn’t seem like there’s been much progress in treating this over the ensuing decade.